JP2023145778A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023145778A5 JP2023145778A5 JP2023129892A JP2023129892A JP2023145778A5 JP 2023145778 A5 JP2023145778 A5 JP 2023145778A5 JP 2023129892 A JP2023129892 A JP 2023129892A JP 2023129892 A JP2023129892 A JP 2023129892A JP 2023145778 A5 JP2023145778 A5 JP 2023145778A5
- Authority
- JP
- Japan
- Prior art keywords
- heavy chain
- population
- light chain
- antibody
- nucleic acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695065P | 2018-07-08 | 2018-07-08 | |
| US62/695,065 | 2018-07-08 | ||
| US201962822671P | 2019-03-22 | 2019-03-22 | |
| US62/822,671 | 2019-03-22 | ||
| PCT/US2019/040843 WO2020014143A1 (en) | 2018-07-08 | 2019-07-08 | Antibody libraries with maximized antibody developability characteristics |
| JP2021523556A JP7332691B2 (ja) | 2018-07-08 | 2019-07-08 | 抗体の開発可能性が最大化された抗体ライブラリー |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523556A Division JP7332691B2 (ja) | 2018-07-08 | 2019-07-08 | 抗体の開発可能性が最大化された抗体ライブラリー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023145778A JP2023145778A (ja) | 2023-10-11 |
| JP2023145778A5 true JP2023145778A5 (https=) | 2024-01-23 |
Family
ID=69102540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523556A Active JP7332691B2 (ja) | 2018-07-08 | 2019-07-08 | 抗体の開発可能性が最大化された抗体ライブラリー |
| JP2023129892A Pending JP2023145778A (ja) | 2018-07-08 | 2023-08-09 | 抗体の開発可能性が最大化された抗体ライブラリー |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523556A Active JP7332691B2 (ja) | 2018-07-08 | 2019-07-08 | 抗体の開発可能性が最大化された抗体ライブラリー |
Country Status (5)
| Country | Link |
|---|---|
| US (8) | US10954508B2 (https=) |
| EP (1) | EP3833685A4 (https=) |
| JP (2) | JP7332691B2 (https=) |
| CA (1) | CA3106115A1 (https=) |
| WO (1) | WO2020014143A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015289874A1 (en) * | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| US20230167165A1 (en) * | 2021-07-07 | 2023-06-01 | Specifica Inc. | Antibody affinity maturation using natural liability-free cdrs |
| CA3244280A1 (en) * | 2022-02-17 | 2023-08-24 | Rules-Based Medicine Inc. | SINGLE-DOMAIN ANTIBODY BANK WITH MAXIMIZED ANTIBODY DEVELOPMENT CHARACTERISTICS |
| WO2023232857A1 (en) * | 2022-06-03 | 2023-12-07 | Ichnos Sciences SA | Common light chain antibody libraries |
| IL320284A (en) * | 2022-10-18 | 2025-06-01 | Tubulis Gmbh | Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof |
| CN118496354A (zh) * | 2023-02-15 | 2024-08-16 | 三优生物医药(上海)有限公司 | 包含共同轻链的抗体库、其制备方法及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2322614A1 (en) | 1995-06-07 | 2011-05-18 | Life Technologies Corporation | Recombinational cloning using engineered recombination sites |
| ATE421976T1 (de) | 1999-05-18 | 2009-02-15 | Dyax Corp | Fab fragmentbibliotheken und verfahren für deren verwendung |
| GB0008419D0 (en) | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| US20060160178A1 (en) | 2003-11-17 | 2006-07-20 | Jonathan Rothberg | Methods of generating antibody diversity in vitro |
| JP2008504356A (ja) * | 2004-06-30 | 2008-02-14 | ドマンティス リミテッド | 炎症性疾患を治療するための組成物及び方法 |
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| PE20110385A1 (es) * | 2008-07-18 | 2011-06-22 | Bristol Myers Squibb Co | Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4 |
| CA2742969A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| EP3246434A1 (en) * | 2015-01-13 | 2017-11-22 | Ewha University-Industry Collaboration Foundation | Method for preparing novel antibody library and library prepared thereby |
| EP3728705A4 (en) * | 2017-12-18 | 2022-01-19 | Charles River Laboratories, Inc. | RADICALLY DIVERSE HUMAN ANTIBODY LIBRARY |
-
2019
- 2019-07-08 EP EP19834483.0A patent/EP3833685A4/en active Pending
- 2019-07-08 WO PCT/US2019/040843 patent/WO2020014143A1/en not_active Ceased
- 2019-07-08 JP JP2021523556A patent/JP7332691B2/ja active Active
- 2019-07-08 CA CA3106115A patent/CA3106115A1/en active Pending
- 2019-07-08 US US16/505,358 patent/US10954508B2/en active Active
-
2021
- 2021-01-29 US US17/163,170 patent/US11920258B2/en active Active
- 2021-03-22 US US17/208,877 patent/US11254931B2/en active Active
-
2023
- 2023-08-09 JP JP2023129892A patent/JP2023145778A/ja active Pending
-
2024
- 2024-02-01 US US18/430,601 patent/US20240384437A1/en active Pending
- 2024-02-29 US US18/592,499 patent/US12344959B2/en active Active
- 2024-02-29 US US18/592,484 patent/US12351946B2/en active Active
- 2024-02-29 US US18/592,473 patent/US12351945B2/en active Active
- 2024-02-29 US US18/592,456 patent/US12359346B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023145778A5 (https=) | ||
| JP2021531822A5 (https=) | ||
| Güssow et al. | [5] Humanization of monoclonal antibodies | |
| EP1032660B1 (en) | Method of identifying binding site domains that retain the capacity of binding to an epitop | |
| AU2008298603B2 (en) | Rationally designed, synthetic antibody libraries and uses therefor | |
| JP4460155B2 (ja) | マウス抗体のヒト化 | |
| US11254931B2 (en) | Antibody libraries with maximized antibody developability characteristics | |
| CN114269789A (zh) | 抗cd24的抗体及其用途 | |
| PT1498427E (pt) | Imunoglobulinas desprovidas de cadeias leves | |
| Roque-Navarro et al. | Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method | |
| CA2401342A1 (en) | Human antibodies against eotaxin and their use | |
| RU99101121A (ru) | Полипептиды, способные к образованию антигенсвязывающих структур со специфичностью к резус-d-антигенам, днк, кодирующая их, способы их получения и применение | |
| CN113603775A (zh) | 抗人白介素-33单克隆抗体及其应用 | |
| US11390964B2 (en) | Polyclonal mixtures of antibodies, and methods of making and using them | |
| JP2024521987A5 (https=) | ||
| JP2025506683A5 (https=) | ||
| JP2025011201A5 (https=) | ||
| US20180334666A1 (en) | Methods for generating bispecific functional agents | |
| KR20030061568A (ko) | Ｂ형 간염 바이러스의 표면 항원에 대한 인간항체 | |
| Gueneau et al. | Round optimization for improved discovery of native bispecific antibodies | |
| CN121362251A (zh) | 抗il-5抗体、其药物组合物及用途 | |
| WO2026080438A1 (en) | Compositions and methods for detection treatment, and prevention of hiv infection | |
| Almagro et al. | Novel approaches in discovery and design of antibody-based therapeutics | |
| AR130792A1 (es) | Proteínas de unión a antígeno | |
| Harris et al. | Reshaped Human Monoclonal Antibodies for Therapy and Passive Immunization |